SCHEMBL23119032

SCHEMBL23119032

CCOC(=O)/C=C(\C)c1n[nH]c2ccc(Br)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.48
KDM4E B2RXH2 1/20 0.45
JAK2 O60674 2/20 0.43
PDPK1 O15530 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRB2 P47870 1/20 0.43
MAPT P10636 2/20 0.40
DYRK1A Q13627 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PAK4 O96013 1/20 0.39
NTRK1 P04629 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23068074 1.00 GSK3B (0.48) GSK3BKDM4EJAK2PDPK1GABRA1
SCHEMBL23068075 1.00 GSK3B (0.48) GSK3BKDM4EJAK2PDPK1GABRA1
SCHEMBL12311279 0.83 KDM4E (0.67) KDM4EMAPTALDH1A1SMN1; SMN2AURKA
SCHEMBL23067964 0.82 PDPK1 (0.50) GSK3BJAK2PDPK1DYRK1ACSF1R
SCHEMBL1636035 0.82 KDM4E (0.66) GSK3BKDM4EJAK2PDPK1GABRA1
SCHEMBL23067965 0.82 PDPK1 (0.50) GSK3BJAK2PDPK1DYRK1ACSF1R
SCHEMBL23792137 0.77 JAK2 (0.50) GSK3BKDM4EJAK2PDPK1GABRA1
SCHEMBL19384339 0.77 GABRA1 (0.60) GSK3BKDM4EJAK2PDPK1GABRA1
SCHEMBL9436096 0.76 PDPK1 (0.59) GSK3BKDM4EJAK2PDPK1DYRK1A
SCHEMBL4782423 0.74 ATM (0.54) GSK3BKDM4EJAK2PDPK1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242543-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2023-08-03 US disclosed
WO-2023056441-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2023-04-06 WO disclosed
WO-2021050824-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242543-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK3, CDK9 GSK3B 155/4885KDM4E 284/4885JAK2 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.